CliffBio
small molecule

ABILIFY MAINTENA KIT

ARIPIPRAZOLE

Loss of exclusivityApril 2034latest FDA-listed patent expiry
CompanyOtsuka Pharmaceutical →View the full company profile on CliffBio

Drug detail

Brand nameABILIFY MAINTENA KIT
Active ingredientARIPIPRAZOLE
Strength400MG
Dosage formFOR SUSPENSION, EXTENDED RELEASE
RouteINTRAMUSCULAR
ModalitySmall molecule
FDA approvalSeptember 2014
Marketing statusRX

Listed patents

PatentExpiresType
11648347April 2034product
10525057March 2034use U-2723
11344547September 2033use U-814
11400087September 2033use U-1632
10980803September 2033use U-543
11154553September 2033use U-3245

More from Otsuka Pharmaceutical

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ABILIFY MAINTENA KIT patent cliff — loss of exclusivity April 2034 | CliffBio